You may also be interested in
Facts & Figures
Facts
Year of Foundation: 1946
Shareholder Structure 2010: 19 shareholders
Group Operating Committee:
Corporate Officers:
- Harald F. Stock, PhD., Chief Executive Officer, Chairman of the Corporate Management Board
- Prof. Dr. Eric-Paul Pâques, President Grünenthal Innovation & Chief Alliance Officer, Vice-Chairman of the Corporate Management Board
- Stefan Genten, Chief Financial Officer & Chief Operating Office
Heads of the Strategic Business Units and Functions:
- Alberto Grua, PhD., Executive Vice President Grünenthal Europe & Australia
- Klaus D. Langner, PhD., Executive Executive Vice President and Chief Operating Officer of Grünenthal Innovation
- Jan Van Ruymbeke, M.D., Executive Vice President Grünenthal Latin America
- Thomas Senderovitz, M.D., Executive Vice President Compound Development & Branding
- Heinz-Gerd Suelmann, PhD., Executive Vice President Global Human Resources
Supervisory Board 2010: 5 members
International Presence 2010: Affiliates in 30 countries worldwide, 5 production sites, headquarters Aachen Germany
Main Business Areas 2010: Pain
Top-Selling Products (Global Brands 2010): Palexia®, Zaldiar®, Tramal®, Transtec®, Norspan®, Versatis®
Figures
| Corporate Figures in Mio € | 2010 | 2009 |
| Revenues | 910 | 881 |
| Revenue Growth vs. Previous Year | 3% | 2% |
| Growth Pain Business1 | + 6.8% | + 4.7% |
| Growth Pain Business Europe2 | + 6.6% | + 4.7% |
| Revenues by regions | ||
| Europe | 700 | 706 |
| Latin America | 133 | 143 |
| Rest of world | 78 | 31 |
| Operating Sales net by main products | 860 | 843 |
| Global Brands Pain | 472 | 443 |
| Palexia® | 4 | 0 |
| Zaldiar® | 167 | 146 |
| Tramal® | 137 | 147 |
| Transtec® / Norspan® | 123 | 123 |
| Versatis® | 41 | 27 |
| Other Global Brands | 88 | 101 |
| Belara® | 65 | 77 |
| Colistin / Colistin CF | 23 | 24 |
| Local / Regional Products | 300 | 299 |
| Research & Development Costs | 207 | 157 |
| R&D Costs Ratio (R&D Costs / Revenues) | 23% | 18% |
| Income before Taxes (IBT) | 344 | 116 |
| Return on Revenue (IBT / Revenue) | 38% | 13% |
| Equity Ratio | 66% | 58% |
| Employees (annual average) | ca. 4,900 | ca. 5,000 |
Our financial statements are published at www.ebundesanzeiger.de (German)
1 Grunenthal's Pain Business excl. partner franchise in Grunenthal countries (acc. IMS)
2 Grunenthal's Pain Business Europe excl. partner franchise in Grunenthal countries (acc. IMS)